Skip to main content
Premium Trial:

Request an Annual Quote

Travis Lacey, Dale Gordon, Gary Altman, Steven Ness

Human Longevity has hired several new senior staff. Travis Lacey was named chief corporate development officer; Dale Gordon was named chief commercial officer; Gary Altman was named chief operating officer; and Steven Ness was named chief services lead. Lacey comes from GE Healthcare where he was the managing director, leading the divestiture practice and portfolio optimization. Before that he was with investment banks Jefferies and R.W. Baird. Gordon was most recently GM of account management at GE Healthcare. Prior to that, he was with EMD Millipore, now Millipore Sigma and part of Merck KGaA. Altman has more than 25 years of experience leading startups and has served as CEO, COO, VP, and GM at various firms. Ness most recently was director of client services at GE Healthcare's Clarient Diagnostics business. Previously, he held medical affairs and marketing positions at Quidel. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.